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Fetal growth restriction (FGR) is an adverse pregnancy outcome associated with signiﬁcant perinatal and paediatric morbidity
and mortality, and an increased risk of chronic disease later in adult life. One of the key causes of adverse pregnancy outcome
is fetal growth restriction (FGR). While a number of maternal, fetal, and environmental factors are known causes of FGR, the
majority of FGR cases remain idiopathic. These idiopathic FGR pregnancies are frequently associated with placental insuﬃciency,
possibly as a result of placental maldevelopment. Understanding the molecular mechanisms of abnormal placental development
in idiopathic FGR is, therefore, of increasing importance. Here, we review our understanding of transcriptional control of normal
placental development and abnormal placental development associated with human idiopathic FGR. We also assess the potential
for understanding transcriptional control as a means for revealing new molecular targets for the detection, diagnosis, and clinical
management of idiopathic FGR.
1.Introduction
1.1. Fetal Growth Restriction. The regulation of fetal growth
is multifactorial and complex. Normal fetal growth is deter-
mined by the genetically predetermined growth potential
and further modulated by maternal, fetal, placental, and
environmental factors [1]. Fetal growth restriction (FGR),
also known as intrauterine growth restriction (IUGR), is
af a i l u r eo ft h ef e t u st or e a c hi t sf u l lg r o w t hp o t e n t i a lf o r
gestation age. FGR is commonly deﬁned as a birth weight of
less than the 10th percentile for gestation, together with evi-
dence of fetal health compromise such as oligohydramnios
and asymmetric fetal growth involving an increased head to
abdominal circumference ratio. Evidence of such underlying
pathology allows clinicians to discriminate between FGR
and healthy small for gestation age (SGA) babies that are
otherwise normal. FGR is associated with an increased
risk of perinatal complications such as prematurity [2],
stillbirth [2–5], neonatal morbidity [5, 6], and mortality
[5, 6]. Adverse outcomes for FGR neonates include impaired
neuropsychological development [7, 8] leading to reduced
intelligence quotients [9, 10]. While FGR can be attributed
toobviousfetal(e.g.,chromosomalabnormalities),placental
(e.g., obvious infarcts), maternal (e.g., tobacco smoking),
and environmental factors (e.g., viral infections), about
7 0 %o fc a s e sd on o th a v eak n o w nc a u s ea n da r et e r m e d
idiopathic FGR. Idiopathic FGR is frequently associated with
placental insuﬃciency [11]. Cordocentesis studies (sampling
of umbilical fetal arterial or venous blood) show features
consistent with chronically inadequate transplacental oxygen
exchange between the mother and FGR fetus [11]. Clinical
features of idiopathic FGR pregnancies include abnormal
umbilical artery Doppler velocimetry [12], oligohydramnios
[13], and asymmetric fetal growth [14].
1.2. Pathology of Placental Dysfunction in FGR. Typically,
the placentae in idiopathic FGR are smaller than their
gestation age-matched controls [15], and they show obvious
morphological defects. Macroscopic placental lesions [12]
are frequently evident, whilst microscopic defects such
as reduced trophoblast proliferation and abnormal villous
vasculature with shorter, less branched terminal villi [16]2 Journal of Pregnancy
are also observed. Another signiﬁcant functional defect is
uteroplacentalischemiaduetofailureoftheplacentalextrav-
illous cytotrophoblast cells to eﬀectively carry out the critical
processes of invasion, transformation, and remodeling of the
spiral arteries in the maternal decidua [17].
At the cellular level, trophoblast function is modulated
in an autocrine/paracrine manner by growth factors, their
binding proteins, and extracellular matrix components of
the placenta (reviewed in [18, 19]). This modulation of tro-
phoblast cell function involves various extracellular signals,
signalling molecules, and consequent receptor activation in
the signalling pathway. Disruption of various important
signalling pathways is observed in placental pathologies that
are associated with abnormal trophoblast function [20].
A consequence of altered placental function in idiopathic
FGR is reduced transfer of oxygen, nutrients, and growth
factors to the fetus, which restricts fetal growth [21]. The
changes observed in FGR placentae are consistent with early
developmental defects [17], but the developmental genes
involved and their molecular mechanism of action are not
known. Several longitudinal studies have demonstrated a
possible causative role for genetic and familial factors, as yet
unidentiﬁed, in human FGR [22, 23].
Current knowledge of the molecular mechanisms of FGR
is limited. Various attempts to understand the molecular
basis of FGR using microarray and proteomics approaches
have revealed signiﬁcant diﬀerences between FGR and
uncomplicated control [24–26] on term placentae and have
shed little light on the regulatory mechanisms that underlie
the early events leading to idiopathic FGR. Murine model
systems, particularly those amenable to genetic manipu-
lation, are therefore of crucial importance in revealing
potentially important regulatory genes that may play a role
in the early stages of human FGR. In many animal model
systems,earlydevelopmentalstagesarecontrolledatthelevel
of transcription factors.
2. TranscriptionalControl of
Placental Development
Growth factors and signalling molecules represent the cue to
which a cell responds by either maintaining or altering its
state of diﬀerentiation [27]. However, it is the transcription
factors, located within the cell nucleus, which determine
how this cue is interpreted and what the cellular response
will be. Transcription factors achieve this by regulating
expression of their target genes within the cell. A large
number of diﬀerent transcription factors play essential roles
in cellular development and diﬀerentiation of various cell
types, including the trophoblast cell type in the placenta
[28,29].Transcriptionfactorsarecategorisedintoafewlarge
families such as the zinc ﬁnger, leucine zipper, helix-loop-
helix, helix-turn-helix, and homeobox genes [30, 31].
3.Homeobox Genes
Homeobox genes (also known as homeotic genes) were
originally discovered in the fruit ﬂy Drosophila, where
they act as transcriptional regulators to control embryonic
morphogenesis (reviewed in [32–34]). These genes contain
a highly conserved 180 base pair homeobox sequence, which
encodes a 60 amino acid homeodomain. Structural analyses
have shown that the homeodomain consists of an evolu-
tionarily conserved helix-turn-helix motif that binds to the
DNA. The speciﬁcity of this binding allows homeodomain
proteins to activate or repress the expression of batteries of
downstream target genes [35].
Most important is that homeobox genes are directly or
indirectly involved in a variety of developmental disorders,
diseases, and cancers (reviewed in [36]). Homeobox genes
are subdivided into the “clustered” homeobox genes known
as “HOX” genes, the “nonclustered” divergent or orphan
HOX-like genes, as well as several distinct classes of atypical
homeodomain containing genes. The HOX family plays
a fundamental role in the embryonic morphogenesis and
were identiﬁed in mammals and vertebrates based on their
sequence homology to the genes of the Drosophila HOM-C
[37, 38]. In mice and humans, the HOX complex is com-
prised of 39 genes that are arranged into four separate chro-
mosomal clusters designated HOX A, B, C, and D [39, 40].
Homeobox genes are grouped together into various
subfamilies based on a variety of criteria such as their
functional and structural characteristics, and these subfam-
ilies of homeobox genes are essential for the control of
speciﬁc aspects of cellular growth and diﬀerentiation [28,
29, 41]. Evidence for the deregulation of certain homeobox
genes in cancer and other diseases provides support for
the idea that homeobox genes are vital for normal mam-
malian development. Furthermore, characterisation of such
homeobox genes may lead to a greater understanding of the
developmental mechanisms, which are disrupted in a variety
of disease states. There is evidence that normal homeobox
gene expression can be altered during a diseased state, such
as decreased expression of Cdx2 in the intestinal epithelium
of patients with colorectal cancers and decreased Meox2
expression in brain endothelial cells of patients aﬀected
by Alzheimer’s disease [36, 42]. Thus, homeobox genes
could be used as disease markers or potential therapeutic
targets of diseases, such as cancer, diabetic wound heal-
ing, lymphedema, Alzheimer’s disease, and stroke due to
atherosclerosis [43–45].
Homeobox gene mutations have also been shown to
cause human congenital disorders such as Waardenburg’s
s y n d r o m et y p e1[ 46, 47] and Aniridia [48]. The homeobox
gene HuP2 has been found to be mutated in patients with
Waardenburg’s syndrome [46, 47], and the congenital eye
disorder Aniridia caused by a mutation in the homeobox
gene designated AN [48].
The clustered homeobox genes, known as HOX, play
a fundamental role in embryological morphogenesis. HOX
gene mutations are implicated in various human malforma-
tions such as hand-foot-genital syndrome, Mowat-Wilson
Syndrome, and Duanes Retraction Syndrome (reviewed in
[36]). There is also an association between mutation in HOX
genes and autism spectrum disorders [49]. More recently,
the Aristaless-related homeobox gene, ARX, was found to
be associated with both X-linked mental retardation and
epilepsy [50, 51].Journal of Pregnancy 3
Mouse knockouts have also provided genetic proof that
homeobox genes regulate embryonic organogenesis and
morphogenesis [52–54]. For example, targeted disruption
of the Hlx homeobox gene (the homolog of human HLX)
in the mouse shows that Hlx plays a fundamental role
in visceral organogenesis [55] .S t u d i e sh a v ed e m o n s t r a t e d
that Hlx mutant mice resulted in developing gut and liver
diverticulum defects. In addition, Hlx mutation also showed
a defect in cell proliferation and resulted in embryonic death
d u et ol i v e rf a i l u r e[ 55]. Furthermore, Hlx is expressed in
mesenchymal cell types during organogenesis in the mouse
placenta [56]. Additionally, recent studies from our labora-
tory have conﬁrmed that placental morphology is severely
aﬀectedinHlxmutantmice(Murthietal.unpublisheddata).
3.1. Homeobox Genes in Murine Placental Development.
Given the highly important role of homeobox genes in
embryonic and adult development, it is not surprising
that homeobox genes also play major roles in controlling
extraembryonic development of the placenta. Homeobox
genes regulate mouse placental cell functions and targeted
gene mutations of homeobox genes in the mouse pro-
duce FGR-like eﬀects. For example, homeobox gene mouse
mutants, Esx1 and Dlx3, produce FGR-like eﬀects in mice
including restricted fetal growth and placental defects [57,
58]. Esx1 expression is restricted to the placenta and is
not expressed in the embryo. Thus, in the Esx1 mutant
mouse, altered placental function is the cause of restricted
fetal growth. Dlx3 and Esx1 mutant mice show speciﬁc
defects in the labyrinthine trophoblast of the chorioallantoic
placenta [57, 58]. In addition, the 3 beta-hydroxysteroid
dehydrogenase gene (3β-HSD), which is important for the
biosynthesis of all active steroid hormones, is a target of
the Dlx3 homeobox gene in the mouse [59]. Therefore,
homeobox genes control important trophoblast functions in
the mouse placenta.
The homeobox gene Cdx2 is expressed in the embryonic
trophectoderm and in the spongiotrophoblast component of
the placenta at later stages of development and is implicated
in the patterning of the extraembryonic membranes of
the mouse placenta [60]. The ﬁnding that Cdx2 homozy-
gous null mutant mice die between 3.5 and 5.5 days as
a consequence of failed implantation suggests that this
homeobox gene may play a role in controlling trophoblast
diﬀerentiation [61].
The placenta speciﬁc–homeobox gene (Psx) also aﬀects
mouse placental development. The Psx transcript was ﬁrst
detected at embryonic day 8.5 and expression persisted until
birth. Psx mRNA is expressed in extraembryonic tissues,
mainly in the placenta, but not in the fetus [62]. Further
studies have shown that the Psx homeobox gene plays a
unique role in the function of diﬀerentiated trophoblast cells
in the murine placenta [63].
Mouse homeobox gene knockouts have also provided
evidence that homeobox genes regulate vascular develop-
ment and angiogenesis in the mouse placenta (reviewed in
[29,41,64]).Therefore,inanimalmodelsystems,homeobox
genes control trophoblast and endothelial cell functions
during placental development.
3.2. A Strategy for Understanding Transcriptional Control
in Normal and FGR-Aﬀected Placentae. Our strategy for
understanding the molecular mechanisms of placental func-
tion in normal and FGR-aﬀected human placentae involved
(i) determining the spatiotemporal expression pattern of
homeobox genes during placental development that have
an “evolutionary history” of regulating cell fate decisions
during embryonic or adult development, (ii) determining
whether speciﬁc homeobox gene expression levels were
changed in FGR-aﬀected placentae compared with gestation
matched controls, (iii) creating in vitro models of placental
cultured cells that “mimic” homeogox gene expression
changes observed on FGR by the use of loss- or gain-of
functionphenotypesusingRNAinterferencesystemsorgene
overexpression plasmids, and (iv) deﬁning the biological
functions of the target genes using in vitro models. These
approaches have been proven very successful in identifying
transcriptional control of endocrine functions during mouse
placental development (reviewed in [28, 29]). Therefore,
identiﬁcation of the homeobox target genes in specialised
cell types of the human placenta can reveal the molecular
pathways responsible for important placental cell functions.
T h e s ep a t h w a y sm a yb ea ﬀected in FGR. Using this novel
approach, more recent studies in our laboratory have
described a potential role for transcriptional control of
homeobox gene HLX in the human placental trophoblast
cells. In the following section, we will summarise our
current understanding of homeobox gene HLX regulation in
human placental development, more speciﬁcally to human
extravillous trophoblast function, as well as give insights into
novel mechanisms of trophoblast dysfunction observed in
FGR-aﬀected pregnancies.
(i) Spatiotemporal Expression Patterns of Homeobox Genes in
the Placenta. Studies in the human placenta have focused
mainly on identifying homeobox genes expressed in the
normal placenta [65, 66], and those showing altered expres-
sion in trophoblastic cancers [67]. The homeobox genes we
and others have identiﬁed to be of potential importance
in the human placenta are DLX3 [59, 68, 69],D L X 4
[70–72], MSX2 and GAX [70], ESX1L [58, 73], and
HLX [74–77]. These genes are potential candidates for
regulating epithelial-mesenchymal cell interactions in the
human placenta. These genes are potential candidates for
regulating epithelial-mesenchymal cell interactions in the
human placenta. These genes are also expressed in the
embryo and play major roles in embryonic development [78,
79]. Microarray expression proﬁling of placental trophoblast
and endothelial cells revealed that novel placental homeobox
genes TGIF, MEIS2E, LIM2,a n dSMAP31-12 are also highly
expressed in trophoblast cells (Murthi et al. unpublished
data).
Few functional studies have been carried out on human
placental homeobox genes. One limited study reported that
the inactivation of homeobox gene DLX4 resulted in altered
rates of trophoblast cell apoptosis [72]. Homeobox gene
DLX3 regulates the expression of the alpha subunit of hCG
[59]a n do f3 - βHSD [69], both of which are important for
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3.3. Homeobox Genes in Human Placental Endothelial Cells.
Knowledge of homeobox genes in human endothelial cells
comes primarily from studies in the cardiovascular system
employing cell culture models such as human umbilical vein
endothelial cells (HUVEC). Homeobox genes are critical
regulators of cardiovasculature development [80]. GAX is a
negative regulator of angiogenesis [81]. HOXB3 promotes
invasive behaviour of endothelial cells in response to angio-
genic stimulation [54], whereas HOXD3 promotes capillary
morphogenesis[82].InHUVECstimulatedwithVEGF,HEX
acts as a negative regulator of angiogenesis [83]. Also in
HUVEC, GAX is an inhibitor of endothelial cell activation
in response to growth factors and tube formation [53].
Previous studies from our laboratory have demonstrated
the expression of homeobox genes HLX, DLX3, DLX4,
MSX2,a n dGAX in placental endothelial cells, and we
showed that novel placental homeobox genes, such asTLX1,
TLX2, TGIF, HEX, PHOX1, MEIS2, HOXB7, and LIM6 were
also expressed in placental endothelial cells [84]. Our ﬁnd-
ingshavehighlightedthepotentialimportanceofthesegenes
inthefundamentalprocessofplacentalangiogenesis.Clearly,
homeobox genes are important regulators of endothelial cell
functions in the embryo and adult but their role in placental
endothelial cells is yet to be determined.
(ii) Homeobox Gene Expression Levels Are Changed in FGR
Placentae Compared with Gestation-Matched Controls. Pre-
vious studies from our laboratory determined the expression
levels of several homeobox genes in a clinically well-deﬁned
idiopathic FGR-aﬀected placentae and gestation-matched
controls[71,73,75].ThecohortofFGR-aﬀectedpregnancies
that was employed was carefully deﬁned in clinical terms
and represented the severe end of spectrum of idiopathic
FGR. The general inclusion criterion for FGR cases was a
birth weight less than the 10th centile for gestation age,
using Australian growth charts. FGR cases were classiﬁed as
idiopathic if there was evidence of an underlying pathology,
judgedbythepresenceofatleasttwoofthefollowingantena-
tal ultrasound diagnostic criteria: abnormal umbilical artery
Doppler ﬂow velocimetry, oligohydramnios as determined
by amniotic ﬂuid index (AFI) <7, or asymmetric growth of
the fetus as measured from the HC (head circumference) to
AC (abdominal circumference) ratio (>1.2). Fetuses showed
reduced growth by the late second and early third trimester.
Reduced villous tree elaboration, diminished surface area
of the placenta, and abnormal end-diastolic blood ﬂow in
the umbilical artery are characteristic of pregnancies with
severely growth-restricted infants [15, 16]. Homeobox genes
HLX [75]a n dESX1L [73] showed decreased expression in
FGR-aﬀected placentae compared with matched controls.
The pattern of normal human fetal growth is complex.
Increases in the rates of fetal weight gain and length increase
are not parallel throughout pregnancy. Evidence suggests
that the maximal growth rate for length is seen in the second
trimester, whereas the maximal rate of weight gain is early
in the third trimester [75, 83]. Guihard-Costa et al. [85]i n
a longitudinal study of human fetal growth have reported a
linear growth rate until 26 weeks and, thereafter, the growth
rate decreased. In our studies, a rapid decline in the levels of
bothHLX andESX1Lexpressionwasobservedfrom27-week
gestation,whichmaycorrespondtothedeclineinthegrowth
rate of the fetus seen in the third trimester [81, 86].
Our studies represented the most comprehensive and
extensive analyses of homeobox genes in placental patholo-
gies undertaken. However, homeobox gene DLX4 showed
increased expression [71] in FGR-aﬀected placentae. Our
observation of altered homeobox gene expression levels,
that is, decreased (HLX) or increased (DLX4) expression in
FGR-placentae compared with gestation matched controls,
prompted us to identify the downstream target genes which
would be aﬀected by changed homeobox gene levels.
(iii) Creating In Vitro Models of Placental Cultured Cells That
“Mimic” Homeobox Gene Expression Changes Observed on
FGR. Homeobox gene HLX is the most characterised in the
human placenta. The HLX gene (also known as HLX1, H2.0-
like homeobox or HB24; OMIM 142995) is a member of the
homeobox family of genes, with homology to the Drosophila
homeobox gene H2.0. A comparison of HLX orthologs in
human and mouse showed that the genes share similar
organization, with four exons and three introns and 85.4%
identity between the human and mouse proteins, suggesting
a similar function in both species [87]. The HLX homeobox
gene was shown to have high expression in haematopoietic
progenitor cells, and lower expression levels in activated
lymphocytes [88].
Our studies demonstrated that HLX is expressed pri-
marily in the proliferating cytotrophoblast cell types in early
placental development and suggested that reduced levels of
HLX are required for cytotrophoblast diﬀerentiation and
that dysregulation of HLX may result in aberrant cytotro-
phoblast proliferation and diﬀerentiation, contributing to
placental pathologies [74].
Furthermore, to identify the functional role of reduced
HLX levels observed in FGR, we simulated reduced
expression levels in extravillous trophoblast derived cell
lines SGHPL4 and HTR8-SV neousing short-interference
RNA (siRNA) speciﬁc for HLX. These two transformed
trophoblast-derived cell lines are well-characterized ﬁrst
trimester-derived human extravillous cytotrophoblast cell
lines and are capable of proliferation, migration, and inva-
sion. The results from this study were not cell line speciﬁc,
since consistent eﬀects were seen in both the cell lines tested.
Our ﬁndings provided evidence of HLX regulation
by cytokines, CSF-1, and growth factors such as HGF,
and established that HLX is an important regulator for
signal transduction mediated proliferation and migration of
human extravillous trophoblast cells [76, 77] suggesting that
HLX may be of pathological signiﬁcance.
(iv) Deﬁning the Biological Functions of the Target Genes
Using In Vitro Models. Understanding the precise regula-
tory mechanisms through which homeobox genes achieve
molecular control during placental development requires
the identiﬁcation of target genes within the downstream
developmental pathways.
Genes involved in regulating cellular mechanisms such
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morphogenesis have been identiﬁed as target genes for many
homeobox genes [89–99]. Thus, homeobox genes act as
“master regulators” of development and control transcrip-
tion by binding to regulatory elements in the promoter
regions of target genes [38].
In the last two decades, the puriﬁcation, cloning, and
characterisation of several homeobox transcription factors,
together with transgenic mouse models, have increased our
knowledge of the molecular basis of placental development.
Whilst loss-of-function studies in the mouse model clearly
demonstrate that homeobox genes such as Cdx2, Cdx4,
Hoxa13,a n ddlx3 are critical for murine placental devel-
opment [60, 68, 100], the target genes regulated by these
homeobox genes have not been investigated in either the
murine or human placenta.
3.4. Identiﬁcation of HLX Target Genes. Previous studies
showed that inhibition of HLX by antisense oligonucleotide
methods impaired CD34+ bone marrow cell proliferation
in response to stimulation by cytokines, whilst inducing
diﬀerentiation of these cells. Moreover, HLX inhibition also
reduced the levels of c-myc, c-fos, cyclin B,a n dp34cdc2
mRNA expression [88]. These cell cycle regulatory genes
were predicted to be involved in the function of trophoblast
cells [101]. By using siRNA-mediated inactivation of HLX
approach, we investigated the mechanisms by which HLX
mediates extravillous trophoblast function in normal and
FGR-aﬀected placentae. We used siRNA in trophoblast
in vitro models such as SGHPL-4 and HTR-8/SVneo
and detected changes in gene expression using pathway-
speciﬁclowdensityPCRarraysforMAP-(mitogen-activated
signaling-)kinase signaling pathways. The downstream tar-
get genes of HLX were identiﬁed as RB1, MYC, EGR1,
CDKN1C, ELK1, CCNB1,a n dJUN. These ﬁndings were
further validated suggesting the observations were not only
consistentintwoindependenttrophoblastcelllines,SGHPL-
4 and HTR-8/SVneo, but was also reﬂected in FGR-aﬀected
human placental tissue. Most importantly, we identiﬁed four
HLX downstream target genes CCNB1, MYC, CDKN1C,a n d
JUN, which were previously identiﬁed as HLX target genes
in haematopoietic progenitor cells [88]a st a r g e t so fHLX
in cultured trophoblast cells. Thus, HLX homeobox gene
targets cell cycle regulatory genes in two independent cell
types.
In the following section, we have described further anal-
yses of candidate downstream target genes of HLX and their
level of expression and potential contribution to functional
abnormalities observed in FGR-aﬀected placentae.
Retinoblastoma-1 (RB1, also known as Rb)i sat u m o r
suppressor gene that was ﬁrst discovered in genetic studies of
hereditary retinoblastoma [102]. RB1 also has a role in other
cancers including osteosarcoma and plays an important role
in regulating cell proliferation and diﬀerentiation [103]. The
product of the RB1 gene is a nuclear phosphoprotein that
may act as an inhibitor of cell proliferation [104]. Addition-
ally, Schubert et al. [105] have demonstrated that RB1 is a
downstream target of the GCMa/Gcm1 transcription factor
inthemouseplacenta.Therefore,RB1hasbeenshowntobea
directtargetoftranscriptionfactors.Inmice,theconstitutive
knockout of RB1 causes embryonic lethality resulting from
defects in placental function [106]r e v i e w e di n[ 107]. Wu
and coworkers [106] have demonstrated that reduction of
RB1 gene expression in the mouse model system resulted in
excessive proliferation of trophoblast cells and a severe dis-
ruption of the normal labyrinth architecture in the placenta.
This was accompanied by a decrease in vascularisation and
a reduction in placental transport function and ultimately
embryonic death [106].
Our ﬁndings demonstrated that RB1 is a direct or
indirect downstream target of the homeobox gene HLX in
cultured human trophoblast cells [108]. Furthermore, RB1 is
expressed in the proximal region of proliferating trophoblast
cells in the trophoblast cell column [109], where HLX is
also expressed [74]. This provided supporting evidence HLX
may act as a regulator of RB1 in trophoblast cells and
that HLX-mediated RB1 expression in trophoblast cells may
reduce trophoblast proliferation. We also observed that RB1
showed the highest relative increase in expression levels
in FGR-aﬀected placentae compared with control placentae
[108]. These data suggest RB1 is a negative regulator of cell
proliferationandthatincreasedRB1expressionlevelsinFGR
may reduce trophoblast proliferation and result in a fewer
number of trophoblast cells available to migrate and invade
into the maternal decidua. This reduction in trophoblast
proliferation may also lead to the shallow, inadequate
remodeling of the maternal spiral arteries associated with
FGR.
MYC is a proto-oncogene that is overexpressed in a wide
range of human cancers. This cell cycle regulator gene is part
ofthepostreceptorintracellularsignalingpathwayforregula-
tion of cell proliferation by growth factors [110]. Depending
on the cellular context, MYC proteins induce either cell
proliferation or apoptosis and they require cooperation with
other oncoproteins and inhibition of apoptotic pathways to
transform cells [111]. Previous studies have determined that
MYC is expressed in the actively proliferating extravillous
trophoblast cells of the human placenta [112–114], where
we have shown HLX to be highly expressed [74]. Results
from our study demonstrated that MYC mRNA expression
wassigniﬁcantlyincreasedwithHLX inactivationincultured
trophoblast cells, suggesting that MYC is a direct or indirect
downstream target gene of HLX [108].
Targeted disruption of c-myc gene (homolog of MYC)
in the mouse model system resulted in severe placental
defects including morphological abnormalities [115]. Sev-
eral embryonic developmental defects were also reported
including abnormalities in the heart, liver, and neural tube
formation. More importantly, embryonic death was also
observed in c-myc knock-out mice due to placental insuf-
ﬁciency [115]. Our ﬁndings showed that MYC expression
wassigniﬁcantlyincreasedinFGR-aﬀectedhumanplacentae,
consistent with the increase in MYC expression in HLX
inactivated cultured trophoblast cells [108]. This suggested
that MYC, as a downstream target gene of HLX,i sa
molecular target associated with idiopathic human FGR.
Therefore, HLX-mediated increase in MYC expression may
contributetoincreasedapoptosisthatisfrequentlyassociated
with FGR.6 Journal of Pregnancy
CDKN1C (p57/kip2) is a member of the CIP/KIP family
of cyclin-dependent kianse inhibitors and has been shown
to inhibit several cyclin-dependent kinase kinase/cyclin
complexes and is a regulator of cell proliferation [116].
Mutations of CDKN1C are implicated in sporadic can-
cers and Beckwith-Wiedemann syndrome suggesting that
it is a tumor suppressor candidate. Larson et al. [117]
have suggested that decreased CDKN1C expression may be
involved in human breast carcinogenesis in vivo. CDKN1C
has recently been recognized as a maternally imprinted gene,
supporting its role for genomic imprinting in the regulation
of embryonic implantation and development and placental
growth, as well as in the pathogenesis of proliferative
trophoblastic diseases [118]. In the normal placenta, strong
nuclear CDKN1C e x p r e s s i o nw a so b s e r v e di ne x t r a v i l l o u s
trophoblast, cytotrophoblast, and implantation-site inter-
stitial trophoblast, but was absent in syncytiotrophoblast
[118]. This expression of CDKN1C in the human placenta
is consistent with the expression pattern of HLX from our
study [74].
Studies have shown that targeted disruption of CDKN1C
in the mouse model system results in severe placental
defects [119]. CDKN1C knock-out mice have displayed
an array of pre-eclampsia symptoms, including placental
abnormalities, hypertension, proteinuria, and premature
labour [119]. Results from our own ﬁndings showed that
CDKN1C expression is signiﬁcantly reduced in cultured
trophoblast cells, therefore, is a direct or indirect target
candidate gene of HLX in cultured trophoblast cells [108].
This suggests that HLX-mediated reduction of CDKN1C
expression may reduce trophoblast proliferation. Further
conﬁrmation of CDKN1C mRNA expression in FGR-
aﬀected human placentae, also show a signiﬁcant decrease
in human idiopathic FGR compared with gestation-matched
controls.
ELK1, as a member of the ETS family, acts as a
transcriptional factor for the MET gene [120], which is
expressed in placental cytotrophoblasts [121]. As with HLX,
ELK1 is also expressed in human extravillous trophoblast
cells [122] and is suggested to play a role in the regulation
of cell proliferation and migration [123]. ETS transcription
factors are also critical for human uterine decidualisation
[124]. Human decidual ﬁbroblasts expressed signiﬁcantly
lessmRNAforthedecidualisationmarkersprolactin,IGFBP-
I, EBAF, TIMP3, decorin, and laminin in the presence of
an antisense oligonucleotide that blocks the translation of
ETS mRNA when compared with decidual ﬁbroblast cells
exposed to a control oligonucleotide [124].
Given our previous ﬁndings of HLX expression in the
human placenta [74] and in the importance of HLX in
trophoblast proliferation [77] and migration [76], ELK1
is a potential target gene of HLX in the control of
trophoblast cell proliferation and migration. Consistently,
results from our observation showed that ELK1 expression
was also signiﬁcantly decreased in FGR-aﬀected human
placentae. Therefore, the cell culture model where siRNA-
mediated reduction of HLX reduces ELK1 was consistent
with decreased levels of HLX and decreased levels of ELK1
in human FGR.
CCNB1 is a regulatory gene expressed predominantly
duringtheG2/Mphaseofthecellcycle,functionallyinvolved
in cell mitosis. Studies have shown expression of CCNB1 in
the villous trophoblast and the extravillous trophoblast cell
types of the human placenta [125, 126], which also correlates
with placental HLX expression from our ﬁndings [74]. This
current study showed that CCNB1 mRNA expression was
signiﬁcantly reduced in cultured trophoblast cells with HLX
inactivation, suggesting that CCNB1 to be a downstream
target gene of HLX. CCNB1 expression was also signiﬁcantly
reduced in FGR-aﬀected placentae compared with controls.
Therefore, our ﬁndings showed that the cell culture model
was consistent with the observed changes seen in HLX
levels in FGR and changes in CCNB1 levels and suggested
a causative role between reduced HLX levels and reduced
CCNB1 levels in FGR.
JUN is a member of the AP-1 family of transcription
factors and is implicated as a key regulator of human
extravilloustrophoblastproliferation,invasion,anddiﬀeren-
tiation[127].Notsurprisingly,JUN isalsostronglyexpressed
in the highly proliferative extravillous trophoblast cells of
the human placenta [127], consistent with HLX expression
in the human placenta [74]. JUN plays a key role in
coordinating steroid hormone actions in a variety of tissues
[128] and is induced by the steroid hormone oestrogen in
the human endometrium. Salmi and Rutanen [129]h a v e
demonstrated a strong expression of JUN in human prolif-
erative endometrium and that JUN expression is decreased
in the human decidua throughout pregnancy [130].
Our own ﬁndings showed signiﬁcantly decreased JUN
expression with HLX gene reduction in cultured trophoblast
cells. This suggests, as a downstream target of HLX, JUN is
regulated by HLX, either directly or indirectly, in order to
aﬀect proliferation, invasion, and diﬀerentiation of extrav-
illous trophoblasts. Consistently, results showed that JUN
expression was also signiﬁcantly decreased in FGR-aﬀected
human placentae compared with control placentae. There-
fore, decreased JUN expression, either directly or indirectly
byHLX,mayresultinanomaloustrophoblastfunctionsasso-
ciated with FGR. Furthermore, HLX-mediated JUN dysreg-
ulation of trophoblast diﬀerentiation and invasion can lead
to abnormal spiral artery remodeling by endovascular tro-
phoblasts, as these endovascular trophoblasts need to diﬀer-
entiate from cytotrophoblasts and invade the maternal spiral
arteries for enhanced blood ﬂow during pregnancy [16].
Thus, the candidate downstream target genes of a
homeobox gene, HLX, are signiﬁcantly altered in human
idiopathic FGR-aﬀectedplacentae, comparedwith gestation-
matched controls. Most importantly, the ﬁndings of our own
study demonstrated that in vitro models for siRNA-mediated
knockdown of HLX expression in placental trophoblast cells
show consistent changes to those observed in human FGR
where HLX levels are reduced. These results suggest that
reduced levels of HLX seen in FGR cause direct or indirect
eﬀects on target genes that have been shown to be altered
in FGR. Therefore, reduced HLX levels directly or indirectly
causegeneexpressionchangesintargetsthathavedeleterious
eﬀects on trophoblast function.Journal of Pregnancy 7
4. Conclusions andFutureDirections
Rapid progress in understanding placental development,
and its regulatory molecules has been achieved in the last
decade. Placental development, as does development of
other embryonic organs, progresses through many step and
some key regulators have now been identiﬁed. However,
more work is required to complete the analyses of both
molecular and cellular events on various human placental
cell types remains. Our current understanding of how
homeobox genes regulate trophoblast functions suggest that
important aspects of regulation are conserved between the
extraembryonicplacentaandembryonicmorphogeneticand
diﬀerentiation events.
It is evident from our ﬁndings that homeobox genes
such as HLX play a critical role in trophoblast function
and involve molecular and cellular mechanisms that have
been observed during diﬀerentiation and morphogenesis of
the embryonic tissues. This may reﬂect the involvement of
HLX in regulating the fundamental process of proliferation,
the regulatory mechanisms of which are likely to be highly
conserved. Studies of targets of other homeobox genes
may reveal the regulation of more specialised placental cell
functions.
The strategy we have employed has resulted in the
identiﬁcation of homeobox genes, which are expressed
in normal placental development and that show altered
expression in FGR. Functional assays following target gene
inactivation in cultured cells reveal that homeobox genes
control important functions in placental cells. The discovery
of targets of homeobox genes has revealed genes, and path-
ways, not previously implicated in FGR. These target genes
and pathways will be further assessed for their therapeutic
and diagnostic potential in future.
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